1. Home
  2. BMRA vs IMRN Comparison

BMRA vs IMRN Comparison

Compare BMRA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

N/A

Current Price

$2.14

Market Cap

6.6M

Sector

Health Care

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.89

Market Cap

7.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMRA
IMRN
Founded
1971
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
7.8M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
BMRA
IMRN
Price
$2.14
$0.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.3K
23.7K
Earning Date
04-13-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,311,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.87
$0.68
52 Week High
$4.60
$2.38

Technical Indicators

Market Signals
Indicator
BMRA
IMRN
Relative Strength Index (RSI) 49.45 57.84
Support Level $2.11 $0.69
Resistance Level $2.23 $1.00
Average True Range (ATR) 0.07 0.06
MACD 0.00 0.01
Stochastic Oscillator 57.89 54.29

Price Performance

Historical Comparison
BMRA
IMRN

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: